



Dorothy L. Rosenthal, M.D.

The ASC Foundation Column

Dorothy L. Rosenthal, M.D., President
The ASC Foundation

In seven short years, the ASC Foundation funds have increased significantly, thanks to the generosity of members, friends of the Society, and our corporate sponsors. Even in a recession such as we have recently faced, members' donations have almost equaled the donor highs of previous years. That's a remarkable record for a small professional organization!

However, if you were at the Denver ASC Annual Scientific Meeting (ASM) this past November, you could feel the enthusiasm of the members who attended, with incredibly professional support from the National Office. The influence of the ASC Foundation was also demonstrated throughout the Meeting: Scholarships for recent graduates of cytotechnology training programs and for pathology residents and cytopathology fellows to attend the Annual Scientific Meeting; Platform presentations and posters written by recipients of grants for research; Grants for Advocacy programs around the globe.

Our [Corporate Partners](#) also continued their support, although generally below the level of previous years. While we are sympathetic for the financial down-turns faced by many corporations and appreciate the loyalty of our usual sponsors, the Foundation Board has decided to look beyond the

companies whose market place is strongly tied to our subspecialty. The programs that our members find essential to their own professional missions need to be enhanced to include partnering with industries that will not produce a conflict of interest. Therefore, the Foundation is rewriting our Case Statement to emphasize the global impact of our field on all patients, young and old, of both genders, and of all nationalities. While the Pap test is still the hallmark of our specialty, the opportunity to sample tumors with minimal morbidity, diagnose the lesion, and then perform tests on the same sample that will indicate the molecular/genetic profile of the lesion is incredibly exciting. We want to be able to take this excitement to companies following the model of the Susan G. Komen Breast Cancer Foundation.

Such efforts take not only a newly rewritten Case Statement, but connections of our members with potential corporate sponsors, far beyond those who have been our sponsors in the past. I am hopeful that any of you who have connections with companies who might be interested in supporting and expanding our programs will let the ASC Foundation know their contact information. We will then follow up. The work of the ASC Foundation is not just the responsibility of the Foundation Board, but of all members. The larger our investment principle becomes, the more programs we can implement with earnings without spending any of the principle.

The ASC Foundation Board urges you to add our efforts to your list of New Year's resolutions by contacting Beth Jenkins (bjenkins@cytopathology.org) or me (drosenthal@jhmi.edu) with any ideas you may have to raise funds that will support the mission of the ASC. Happy and Healthy New Year to all of you! ■



Enabling the future is what the ASC Foundation is all about - your giving works, and makes a difference in the lives of others!

Dear Dr. Howell,

Please extend my sincerest thanks to the Foundation for awarding me the Cytotechnology Molecular Training Scholarship. I am thrilled to have been chosen. This scholarship will help me achieve my goals of being a multi-disciplined cytotechnologist. I am preparing for the changes ahead and I hope to show my colleagues that adopting new skill sets is achievable as a working cytotechnologist. This has been a challenging experience and being awarded the scholarship has renewed my spirit.



Again, thank you to the Foundation for your support in my achieving these accomplishments.

Sincerely,
Christine Panetti, B.S., CT(ASCP)